Meeting
2023 ASCO Annual Meeting
A feasibility study of 177Lu-PSMA radioligand therapy alternated with radium-223 in patients with bone-metastatic, oligo-metastatic, hormone-sensitive prostate cancer after curative therapy: The DUET study.
Authors
André Vis
Amsterdam UMC, location VUMC, Amsterdam, Netherlands
André Vis , Rosemarijn Ettema , Harry Hendrikse , Suzanne van der Gaag , Daniela Elena Oprea-Lager
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NL81658.029.22
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5113)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5113
Abstract #
TPS5113
Poster Bd #
199b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.
First Author: David James VanderWeele
Poster
2024 ASCO Genitourinary Cancers Symposium
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
First Author: Charlotte Hawkins
Poster
2024 ASCO Genitourinary Cancers Symposium
Patient characteristics, treatment patterns, and outcomes among early adopters of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617): A real-world United States (US) study.
First Author: Xiao X. Wei
Poster
2024 ASCO Genitourinary Cancers Symposium
Chromatin modifications on plasma ctDNA as a tool to phenotype castration-resistant prostate cancer.
First Author: Asli Munzur